It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dectin-1 (gene Clec7a), a receptor for β-glucans, plays important roles in the host defense against fungi and immune homeostasis of the intestine. Although this molecule is also suggested to be involved in the regulation of tumorigenesis, the role in intestinal tumor development remains to be elucidated. In this study, we find that azoxymethane-dextran-sodium-sulfate-induced and ApcMin-induced intestinal tumorigenesis are suppressed in Clec7a−/− mice independently from commensal microbiota. Dectin-1 is preferentially expressed on myeloid-derived suppressor cells (MDSCs). In the Clec7a−/− mouse colon, the proportion of MDSCs and MDSC-derived prostaglandin E2 (PGE2) levels are reduced, while the expression of IL-22 binding protein (IL-22BP; gene Il22ra2) is upregulated. Dectin-1 signaling induces PGE2-synthesizing enzymes and PGE2 suppresses Il22ra2 expression in vitro and in vivo. Administration of short chain β-glucan laminarin, an antagonist of Dectin-1, suppresses the development of mouse colorectal tumors. Furthermore, in patients with colorectal cancer (CRC), the expression of CLEC7A is also observed in MDSCs and correlated with the death rate and tumor severity. Dectin-1 signaling upregulates PGE2-synthesizing enzyme expression and PGE2 suppresses IL22RA2 expression in human CRC-infiltrating cells. These observations indicate a role of the Dectin-1-PGE2-IL-22BP axis in regulating intestinal tumorigenesis, suggesting Dectin-1 as a potential target for CRC therapy.
The effect of β-glucans and their receptor Dectin-1 in tumor development remains controversial. Here the authors show that Dectin-1 signaling promotes the development of colorectal cancer (CRC) by inducing prostaglandin E2 production in myeloid-derived suppressor cells and by suppressing IL-22BP expression, suggesting dectin-1 blockade as a potential therapeutic target for CRC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
2 Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
3 Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
4 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
5 Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
6 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
7 Sun Yat-sen University, Department of Anesthesiology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
8 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
9 Tokyo University of Pharmacy and Life Sciences, Hachioji, Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo, Japan (GRID:grid.410785.f) (ISNI:0000 0001 0659 6325)
10 Boehringer Ingelheim USA, Ridgefield, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717)